Table 1.
Legend?
| Characteristics | Early (n=186) | Advance (n=96) | p |
|---|---|---|---|
| Age (years) | 52.40 ± 10.16 | 53.71 ± 9.50 | 0.545 |
| Menarche (years) | 12.45 ± 0.98 | 12.21 ± 0.87 | 0.262 |
| Parity (n,%) | |||
| 1 | 3 (33.3%) | 6 (66.7%) | 0.72 |
| 2 | 63 (63.6%) | 36 (36.4%) | |
| 3 | 69 (71.9%) | 9 (28.1%) | |
| 4 | 42 (66.7%) | 21 (33.3%) | |
| 5 | 9 (60%) | 6 (40%) | |
| FIGO Stage (n,%) | |||
| I | 78 (41.9%) | - | |
| II | 108 (58.1%) | - | - |
| III | - | 75 (78.1%) | |
| IV | - | 21 (21.9%) | |
| Histopathology | 0.244 | ||
| Squamous Cell Carcinoma | 111 (61.7%) | 69 (38.3%) | |
| Adenocarcinoma | 75 (73.5%) | 27 (26.5%) | |
| Haemoglobin (g/dl) | 11.48 ± 1.84 | 10.56 ± 1.83 | 0.030* |
| White Blood Cell (109/L) | 8.53 ± 4.79 | 12.41 ± 6.04 | 0.001* |
| Neutrophil (109/L) | 5.85 ± 4.71 | 10.14 ± 5.88 | <0.001* |
| Monosit (109/L) | 0.57 ± 0.23 | 0.61 ± 0.23 | 0.4 |
| Lymphocyte (109/L) | 1.36 ± 0.67 | 1.78 ± 0.73 | 0.008* |
| Basophill (109/L) | 0.05 ± 0.03 | 0.07 ± 0.05 | 0.088 |
| Platelet (109/L) | 281.75 ± 89.1 | 318 ± 160.74 | 0.041* |
| NLR | 2.68 (0.88-34.62) | 7.58 (1.36-33.20) | <0.001* |
| BLR | 0.03 ± 0.01 | 0.06 ± 0.06 | 0.005* |
| MLR | 0.36 ± 0.18 | 0.53 ± 0.28 | 0.001* |
| PLR | 145.40 (72.10-533.25) | 247.89 (97.10-707.11) | 0.001* |
*
statistically significant (p<0.05); SD, Standard Deviations; NLR, neutrophil-to-lymphocyte ratio; BLR, basophil-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.